PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now looking at the association with diabetes and metabolic disease.
| less than a minute read
Checkpoint Inhibitors and Diabetes
Get in touch
Get in touch
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin. Scientists at Boston Children’s Hospital have come up with a way to thwart this wayward autoimmune reaction, and it involves a protein that plays a prominent role in new immunotherapy treatments for cancer: PD-L1.
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-10-08-10-50-28-575-67050e74c71f57809f6d0411.jpg)
Introduction Over the next 2 months, the DLA Piper Life Sciences Blog: Cortex will feature a series of articles providing an insight into...
Latest Insights
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-12-20-00-19-07-074-6764b7fb8b43d2162bbda63e.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-12-17-10-04-22-244-67614ca6e47d4e3f62efe626.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-12-16-09-34-16-975-675ff418f1680c6c88e5b5fa.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-12-10-12-27-55-733-A26208_Life_Sciences_Brochure_November_Brochure_English_V1_thumbnail_1.png)
